Skip to main content
NCBI home page
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Acad Emerg Med. 2014 Nov 24;21(12):1361–1369. doi: 10.1111/acem.12526

Sex- and Gender-Specific Research Priorities for the Emergency Management of Heart Failure and Acute Arrhythmia: Proceedings from the 2014 AEM Consensus Conference Cardiovascular Research Workgroup

Alyson J McGregor 1, Frank F Peacock 1, Anna Marie Chang 1, Basmah Safdar 1, Deborah Diercks 1
PMCID: PMC4284822  NIHMSID: NIHMS648533  PMID: 25422074

Abstract

The emergency department (ED) is the point of first contact for patients with acute heart failure and arrhythmias, with one million annual ED visits in the United States. Although the total numbers of men and women living with heart failure are similar, female patients are underrepresented in clinical studies, with current knowledge predominantly based on data from male patients. This has led to an under-appreciation of the sex-specific differences in clinical characteristics and pathophysiology-based management of heart failure. Similar disparities have been found in management of acute arrhythmias, especially atrial arrhythmias that lead to an increased risk of stroke in women. Additionally, peripartum and postpartum cardiomyopathy represent a diagnostic and treatment dilemma. This article is the result of a breakout session in the cardiovascular and resuscitation work group of the 2014 Academic Emergency Medicine consensus conference “Gender-Specific Research in Emergency Medicine: Investigate, Understand, and Translate How Gender Affects Patient Outcomes.” A nominal group technique was used to identify and prioritize themes and research questions using electronic mail, monthly conference calls, in-person meetings, and web-based surveys between June 2013 and May 2014. Consensus was achieved through three rounds of nomination followed by the meeting on May 13, 2014, and resulted in seven priority themes that are essential to the common complex clinical syndrome of heart failure for both men and women, and include the areas of pathophysiology, presentation and symptomatology, diagnostic strategies using biomarkers, treatment, and mortality, with special consideration to arrhythmia management and pregnancy.

INTRODUCTION

Heart failure, a major cause of cardiac death, is a complex clinical syndrome that can result from any cardiac disorder. Among older patients, heart failure represents the greatest health care burden in developed countries, affecting 5 million patients in the United States with the incidence steadily increasing in both men and women, with a slightly greater proportionality in men.1,2 The emergency department (ED) is often the point of first contact for these patients and has seen a 20% increase in visits over the last decade.3 It is a common discharge diagnosis, particularly in elderly women, and leads to a significant economic burden, with over 34.4 billion dollars spent in 2010.4,5 With underrepresentation of females in clinical studies,6 evidence relating to pathophysiology, etiology, clinical presentation, treatment, and outcome is predominantly based on data from male patients.7 This has led to differences in clinical characteristics between men and women being unrecognized or unknown. This article outlines the consensus recommendations made by the 2014 Academic Emergency Medicine (AEM) consensus conference for future research in the seven priority domains of heart failure, including pathyphysiology, presentation and symptomatology, diagnosis using biomarkers, treatment, and mortality. Additional recommendations are presented for arrhythmias and concerns surrounding heart failure in pregnancy.

METHODS

The priority themes and research questions presented in this manuscript were assembled through an iterative consensus-driven process using a nominal group technique (NGT) as described in the executive summary.8 The executive committee and conference leaders assembled a diverse group of stakeholders and experts who participated in the preconference monthly phone calls, which resulted in progressive refinement of surveys regarding themes and research questions using the NGT between June 2013 and May 2014. The method used to identify the participants is further described in the executive summary.8

Prior to the AEM consensus conference, a preconference survey eliciting open-ended feedback regarding the key themes and research questions identified was sent to all AEM peer reviewers. Responders’ demographics and a list of additional themes that did not qualify for the consensus process are summarized in the article from the emergency diagnosis and management of coronary artery disease breakout group from the cardiovascular research workgroup.9

On May 13, 2014, 45 stakeholders participated in the final iteration of the consensus process (see list in note). The group composition is described further in the coronary artery disease breakout group.9 Anonymous voting was conducted with Poll Everywhere, with paper surveys as back-up. The process details are described elsewhere.8 Data were entered into an electronic spreadsheet (Microsoft Excel) and descriptive analyses were used to tabulate the results.

CONSENSUS RESULTS

This article presents the results of both iterative electronic surveys as well as the in-person meeting on the day of the consensus conference. Seven major themes related to the emergency care of heart failure and arrhythmias were identified and are presented along with the research questions with high agreement on related importance. Questions that were related to the priority themes that underwent further voting at the consensus conference are presented in Table 1.

Table 1.

Ranked Order of Consensus-Driven Research Questions

Rank Consensus-based Questions (voted in degree of important from highest to lowest) Mean Likert Score
(Range 0–5)
1. In patients with heart failure are there interactions between comorbidities and gender impact mortality rates? 4.28
2. How should we define heart failure with preserved ejection fraction by non-invasive methods for acute ED presentations? 3.92
3. In patients with heart failure with preserved ejection fraction, are there risk factors that distinguish physiological discomfort of pregnancy from heart failure with preserved ejection fraction? 3.78
4. In patients presenting to the ED with heart failure, are there gender-specific clinical characteristics that can be identified in young patients at risk so that early referral and preventive management can be provided? 3.65
5. In patients presenting to the ED with heart failure, are there new screening tests for heart failure with preserved ejection fraction that can be used to develop an ED-based registry? 3.33
6. In patients with heart failure can sex specific questionnaires be used to prognosticate gender-specific outcomes? 2.83
Open in a new tab

Recommendation #1: Pathophysiology

Heart failure is a clinical syndrome defined by characteristic symptoms and physical findings. It is characterized into two main entities based on echocardiographic findings: heart failure with reduced ejection fraction, or with preserved ejection fraction, which is variably defined as a left ventricle ejection fraction (LVEF) greater than 40%, 45%, or 50%.10 The former is more common in men, and is primarily related to coronary artery disease, while the latter is more common in women and less commonly associated with ischemia.11,12

There are a number of contributors to the sex discrepancy in heart failure with preserved ejection fraction pathophysiology and sex effects on cardiovascular aging. They are important to understand to devise sex-specific management for these patients. Beginning at puberty, left ventricular chamber size and mass are 15% to 40% lower in women than in men, and these differences persist even after adjustment for smaller body size in women.13 However, women are shown to have higher left ventricular systolic function independent of this ventricular volume.14

Despite having similar peripheral hemodynamics, there are significant sex differences in central hemodynamics. Left ventricular diastolic dysfunction significantly correlates with parameters representing arterial stiffness in women, but not in men.15 Also, there are fundamental differences between men and women in the left ventricular response to chronic load alteration. Males are more likely to develop eccentric left ventricular remodeling with stress, whereas females develop more concentric remodeling.16 Each of these sex dimorphisms becomes more pronounced after menopause. This data suggest that sex-specific maladaptions to hypertensive aging in women may underlie greater risk of heart failure with preserved ejection fraction.

Priority Questions

  1. In patients presenting to the ED with heart failure, are there acute management therapies based upon the known pathophysiologic differences in heart failure with preserved vs reduced ejection fraction that improve outcomes?

Recommendation #2: Presentation and Symptomatology

The presentations for women and men differ in heart failure, often due to the physiology of disease. In one study, women were more likely to present with “new onset” heart failure compared to men.17 Women tend to have different comorbidities and causes of heart failure. For example, hypertension, atrial fibrillation, and valvular heart disease are more common causes of acute heart failure in women; ischemic causes are common in men instead.18 Women more often have diabetes, anemia, and thyroid diseases as comorbidities. Women with heart failure tend to be older than men in most studies; it is unclear if this is due to a protective effect of estrogen. Women tend to have higher systolic blood pressures at presentation, more often present with orthopnea, rales but not edema, with other signs of congestion similar to men.19 This is likely due to higher prevalence of heart failure with preserved ejection fraction in this cohort.

To assess the effect of heart failure on patient’s lives, it is necessary to survey the population. The Kansas City Cardiomyopathy Questionnaire has been found to be a validated measure in patients with reduced and preserved ejection fraction.20 Several studies have shown that even after controlling for ejection fraction, women have significantly worse general life satisfaction, physical function, and social and general quality of life scores compared to men.21,22 It is unclear why there is a difference in quality of life between men and women with heart failure. Despite these differences, men and women have similar 30-day readmission rates for heart failure.23

Priority Questions

  1. In patients with heart failure, are there the key biologic factors that account for sex-variable presentations?

  2. In patients with heart failure, do sex-specific comorbidities affect the presentation and symptom management?

Recommendation #3: Diagnosis Using Biomarkers

B-type natriuretic peptides (BNP) levels are commonly used in the diagnosis and risk stratification of patients presenting with dyspnea that is concerning for heart failure. Prior studies have shown differences in BNP levels by sex. BNP is released and stored in secretory granules as proBNP in the ventricles, and to a small extent the atria. It is activated by volume overload and myocardial stretch, and released into the plasma in its active form BNP.

When evaluating sex differences in BNP levels it is important to identify the patient population being evaluated. In population-based studies, BNP levels have been shown to be higher in women than men. In a study of 2,042 randomly selected residents of Olmstead County in Minnesota, plasma BNP was shown to be 32% higher in women than men (95% CI = 15% to 51%), irrespective of the assay.24 The authors in part attribute this difference to the use of hormone replacement therapy (HRT), as those women on HRT after controlling for age show a 21% (95% CI = 6% to 40%) higher value than women not on HRT. This data provides some evidence that BNP levels are related to hormonal status.25 However, in studies that focus on patients with cardiomyopathy, men have higher circulating levels of natriuretic hormones than women.26 Despite the elevated BNP level found in women in general population studies, elevation of BNP levels after adjustment for other cardiac risk factors is a strong predictor of the development of heart failure, with a hazards ratio of 8.5.27

In patients presenting to the ED with symptoms suggestive of heart failure, measurement of BNP levels is often used as a diagnostic test. Despite differences in population studies, there are no differences in the diagnostic accuracy of BNP assays by sex.28,29 In the Breathing Not Properly study of 1,586 patients who presented to the ED with acute dyspnea, the areas under the curve were similar between women and men (0.870 and 0.918, respectively).29 These studies provide evidence that in the acute care setting the diagnostic accuracy of BNP does not vary by sex.

BNP levels have also been used to assess the prognosis of patients presenting with heart failure. In the BASEL study, regression analyses of BNP levels >500 pg/ml indicated a 5.1-fold increase in mortality for women (95% CI = 3.0 to 8.5, p < 0.001) versus a 1.8-fold increase in men (95% CI = 1.2 to 2.6; p = 0.007).30 In another study that identified variables associated with prognosis in subjects with advanced heart failure, BNP was identified as a strong predictor in sex-based models.31 There appears to be an interaction between BNP levels, sex, and ejection fraction. A large registry study showed that for hospitalized heart failure patients with reduced ejection fraction, men had a higher in hospital mortality rate than women for any given BNP level between the values 500 to 3,000 pg/mL. However, among patients with preserved ejection fraction, sex differences did not exist when BNP levels were adjusted for confounders.32

Priority Questions

  1. In patients with acute heart failure, do sex-specific marker cutoffs for BNP improve diagnosis and prognosis of heart failure with preserved and reduced ejection fraction?

Recommendation #4: Treatment

Heart failure with reduced ejection fraction or with preserved ejection fraction has similar mortality (20% to 30% annual) and readmission rates (30% at 3-months), even though heart failure with preserved ejection fraction is less commonly associated with ischemic heart disease, the number one cause of mortality.33 This is because while clinical trials have shown a mortality benefit of angiotensin-converting enzyme (ACE) inhibitors, beta blockers, aldosterone antagonists, and resynchronization in cases with reduced ejection fraction, the same has not been demonstrated for those patients with preserved ejection fraction.34 Several key trials in patients with preserved ejection fraction have demonstrated improvement of diastolic function, neurohormonal changes, and readmission rates, but none have altered composite cardiac outcomes.35 Although women are diagnosed more often with heart failure with preserve ejection fraction, diuresed less intensely, and hospitalized longer and more often, more men die with this condition.36 The disparities by sex call for more collaborative trials for treatment of NY class IV heart failure.

The current guidelines recommend use of intravenous diuretics, nitrates, and ionotropes, as well as improving ventilation (intubation or biphasic positive pressure ventilation), in acute management of decompensated heart failure. The evidence is better studied for those with reduced ejection fraction, but same recommendations have been extrapolated to decompensationi patients with preserved ejection fraction.34 The factors that promote fluid retention and precipitate heart failure are similar in patients with systolic heart failure and those with diastolic heart failure. These factors include tachycardia, uncontrolled hypertension, atrial fibrillation, non-compliance with medications, myocardial ischemia, anemia, renal insufficiency, and overindulgence in salty foods. The consensus is to treat the underlying causes such as hypertension, tachycardia, use of ACE inhibitors,37 aldosterone,38 or beta blockers,39 and novel therapies such as phosphodiesterase inhibitors or late sodium channel blockers. Caution is advised for aggressive diuresis as preserved ejection fraction patients are more prone to hypotension, being dependent on higher left ventricular filling pressures. Not much is known about the sex variation in execution of these treatment recommendations including acute medication use in the ED, use of non-invasive ventilation or intubation, and rates of intensive care unit admissions. A review of clinicaltrials.gov revealed other small experimental studies using inorganic nitrates, furosemide with dopamine, and ranolazine, but none are testing therapies for acute management of heart failure or are sex-specific. There is also lack of sex-specific reports of basic science results leading to a gap in translation in heart failure clinical trials.40 For end-stage heart failure, women are referred for destination therapy later, comprise 30% of the recipients, and have higher post-procedure complication rates compared to men. They also exhibit greater disability from heart failure as compared to men.39[41] Finally, there are no sex-specific guidelines for palliative care options for the patients with end stage cardiomyopathy.

Priority Questions

  1. What are key sex-specific outcome measures for treatment of heart failure with preserved and reduced ejection fraction?

  2. What are the sex-specific variations in acute management of heart failure that could influence short-term prognosis as well as readmissions?

  3. What is the role of acute diagnostics in tailored sex-specific treatment for heart failure in the ED (biomarkers, point-of-care ultrasound, right heart catheterization, etc.)?

Recommendation #5: Mortality Differences

The American Heart Association reported that in 2010 there were over 57,000 deaths from heart failure. Of these deaths the majority were in women.42 Studies have reported that there are differences in presentation and treatment of women with heart failure. Studies in chronic heart failure patients show that women have a lower mortality rate even after adjusting for ejection fraction.43 Although there have been studies looking at mortality rates by sex in patients with chronic heart failure, fewer data are available to determine the risk of mortality by sex in acute heart failure patients.

In a large trial of women hospitalized with acute heart failure and impaired renal function, age-adjusted 180-day mortality was lower in women (HR 0.74; 95% CI = 0.59 to 0.93), but this difference was negated in multi-variable risk adjusted models.44 These data are not consistent with the report of no difference in long-term mortality in women with reduced ejection fraction reported in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) (men 27% vs. women 24%, multivariate hazard ratio 1.04, p = 0.61), or cardiovascular mortality plus heart failure hospitalization (men 42% vs. women 39%, multivariate hazard ratio 1.11, p = 0.10).45 A large prospective cohort study of patients hospitalized with acute heart failure in Israel reported that women tended toward an increased risk for early (≤ 6 month) mortality (adjusted hazard ratio [HR], 1.16; 95% CI = 0.96 to 1.41; P = 0.13), whereas men had significantly increased risk for late (>6 months) mortality (adjusted HR, 1.25; 95% CI = 1.09 to 1.43, P = 0.001).46 In an analysis of the Acute Decompensated Heart Failure National Registry (ADHERE), which includes patients hospitalized with acute heart failure, despite disparities in treatment, the risk-adjusted in-hospital mortality (adjusted odds ratio 0.974; 95% CI = 0.910 to 1.042; P = 0.4390) was similar in both sexes.47

Data regarding mortality rates in patients with acute heart failure are varied. Registry data that include the entire spectrum are not consistent in the risk of mortality by sex. Variations in conclusions may be based on risk adjusted modeling strategies, the variation in populations being studied, and geographic variations in care.

Recommendation #6: Arrhythmias

Physiology

There are important sex differences in cardiac electrophysiology that alter the epidemiology, presentation, and prognosis of various arrhythmias. For example, women have higher resting heart rates and lower QRS voltage than men (even after adjustment for differences in left ventricular mass and body weight).

There are also sex differences in the prevalence and presentation of various arrhythmias. Atrioventricular nodal reentrant tachycardia is twice as common in women, and atrioventricular reentrant tachycardia occurring in Wolff-Parkinson-White syndrome is more common in men. Further, atrial and ventricular fibrillation occurs more frequently in men with Wolff-Parkinson-White syndrome.48 Hormones may play a causal role in the sex differences of various arrhythmias. Women suffer more frequent and longer-lasting episodes of supraventricular tachycardia as well as an increased frequency of ventricular ectopic beats during the lacteal phase of the menstrual cycle.49

Electrocardiographically, women have longer QT intervalS. This puts them at an increased risk for drug-induced torsadesde pointes (TdP), predisposing them to higher rates of drug induced TdP.50 Sex differences in ventricular tachyarrhythmia susceptibility likely result from the effects of several underlying characteristics that differ in males and females. This includes genetic differences for key repolarizing potassium channels and the effect of sex steroid hormones acutely modifying electrical activity. The implications of these differences may explain why before age 15 years, males with long QT syndrome suffer a higher risk of sudden cardiac death (SCD), but after age 15 years females suffer greater risk.51

Atrial Fibrillation

While men may more frequently suffer from atrial fibrillation, when it occurs women are at higher risk for both stroke and death, independent of other risk factors. Consequently, the Stroke Prevention in Atrial Fibrillation,52 Framingham risk,53 and the CHADS2-VACS54 scoring systems all include “female gender” as an important parameter for stroke risk assessment. Other sex-dependent differences exist. At hospital admission for atrial fibrillation, women tend to be older, and present with higher CHADS2 risk scores. They experience longer (>24 hours) and more symptomatic episodes of atrial fibrillation, they have more frequent recurrences, with significantly higher ventricular rates,55 and women with atrial fibrillation ultimately suffer a lower quality of life vs. men.56

Overall, treatment for atrial fibrillation is more conservative in women. Despite these described risk profiles, women are less likely to receive anticoagulation and ablation procedures compared to men. And while conversion to normal sinus rhythm is equally successful in both sexes, females receive significantly less rhythm control than men, with men being more likely to undergo electrical cardioversion than women.57 It is unclear whether these differences are related to variation in consent or communication of risk.

If treated, women benefit from a greater reduction in thromboembolic events (adjusted relative risk 0.4 for women vs. 0.6 for men, p <0.01) and when anticoagulant therapy is prescribed, women are more likely to fill their warfarin prescriptions within 30 days.55[58] Adverse events related to vitamin K antagonists are similar between men and women, although large studies do find outcome differences between sexes.59 Even in cohorts with patients older than 80 years, the overall bleeding risk as a result of vitamin K antagonist therapy is similar between men and women. In the older cohort, males suffer higher rate of bleeding complications, while females have a slightly higher rate of stroke, which suggests that older women may derive a higher net clinical benefit with anticoagulant treatment.60

Newer oral anticoagulants are now available. Dabigitran, a direct thrombin inhibitor, was studied in 18,113 patients with nonvalvular atrial fibrillation in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial: there was no interaction regarding outcomes or efficacy between women and men.61 Similarly, the factor Xa inhibitors, rivaroxaban and apixaban, were evaluated in the 14,264 patient ROCKET-AF trial59[62] and the 18,201 patient ARISTOTLE63 trial, and neither reported any sex-related efficacy or adverse event differences.

Finally, radiofrequency catheter ablation is a therapeutic option for atrial fibrillation patients failing arrhythmia control. Despite similar rates of successful outcomes with this procedure, when compared to men, women are under-referred and referred later. When they are referred, they are older, suffer higher rates of hypertension, and have larger left atrial dimension at the time of the procedure.64

Sudden Cardiac Death

For all age groups, women have approximately half the risk of sudden cardiac arrest (SCA) vs. men, and are less likely to have coronary artery disease at the time of an SCA event. While a history of heart failure increases the risk of SCA five-fold in both sexes, the absolute risk of SCA in women is one-third of that in men.65

When women suffer SCA, despite occurring at an older age, suffering higher prevalence of SCA in the home, and having higher rates of pulseless electrical activity, women are more likely to have return of spontaneous circulation and survive from ventricular fibrillation and pulseless electrical activity. Ultimately, women are more likely to survive to hospital discharge (OR 1.85; 95% CI = 1.12 to 3.04) following SCA.66

Implantable Cardiac Devices

Implantable cardioverter defibrillators (ICDs) decrease mortality when used for primary and secondary prevention of sudden cardiac death. Although early trials suggested a less robust response in women, this was likely the result of the few women enrolled in these investigations. Recent reports, with more equal sex distributions, demonstrate similar outcome improvement to men.67 Women do not receive implantable cardioverter defibrillators implantation at similar rates to men. In 13,000 hospitalized systolic heart failure (LVEF <30%) patients, among those eligible for implantable cardioverter defibrillators therapy, the adjusted odds of implantable cardioverter defibrillators use were 0.62 for white women and 0.56 for African American women, compared to white men.68 Finally, in regards to cardiac resynchronization therapy, women realize greater benefit in terms of reduced numbers of hospitalizations and more robust reverse ventricular remodeling. Why this sex difference occurs is not well described, and additional investigation is needed.

Priority Questions

  1. In patients with sudden cardiac death, is there a sex-related biological basis for the differences in risks?

  2. In patients with atrial fibrillation, are there sex-related factors that are associated with quality of life?

  3. In patients with atrial fibrillation, do older women treated with oral anticoagulants have a superior net clinical benefit compared to men?

Recommendation #7: Special Concerns Surrounding Pregnancy: Peripartum and Postpartum Cardiomyopathy

A life-threatening disease of uncertain etiology found in previously healthy women has been termed peripartum/postpartum cardiomyopathy (PPCM), and represents a diagnostic and treatment dilemma. The initial presentation is often challenging, and there are no extended prospective studies of PPCM to date.69 Due to advanced maternal age, the incidence of PPCM in the United States is increasing,70 and is estimated to be approximately 1 in 3,200 deliveries. The risk and severity of PPCM in a subsequent pregnancy are increased by 20% to 50%,71 making the initial diagnosis imperative.

The etiology of PPCM is largely unknown, but inflammation, autoimmune processes, apoptosis, viral infections, malnutrition, hormonal abnormalities, stress-activated cytokines, and endothelial dysfunction are proposed mechanisms.72 Recent data indicate cleavage of the nursing hormone prolactin by catepsin D results in oxidative stress on the endothelium, cardiac vasculature, and cardiomyocyte function.73 Echocardiographic evaluation and BNP levels74 are advisable for the early diagnosis of PPCM in patients with preeclampsia who are suspected of having heart failuere.75,76 The high prevalence of elevated NT-proBNP, activated cathepsin D, and 16kDa prolactin in the serum of PPCM patients may be helpful towards a disease-specific biomarker profile.

At present, PPCM is treated according to the guidelines for dilated cardiomyopathy without specific therapy or drug alterations targeting pregnant or lactating women with PPCM.77 Small trials have shown the addition of bromocriptine, a dopamine D2 receptor agonist that blocks prolactin, appeared to improve LVEF and a composite clinical outcome in women with acute severe PPCM.69,78 Also, pentoxifylline in addition to conventional therapy improved the combined clinical end-points of functional status, cardiac function, and death.79 While investigations continue on the molecular basis of PPCM, controlled trials are needed for potential new treatments – including apheresis, immunosuppresion, immunoadsorption, and antiviral agents.80,81

CONCLUSIONS

The sex differences in pathophysiology, presentation, diagnosis, and treatment of acute heart failure and arrhythmia need to be highlighted in order to serve as a foundation to address the gaps in knowledge within both basic and applied research. The consensus approach resulted in the development of seven themes with specific research recommendations to be used as priority areas for future EM investigators. The research questions discussed here do not exhaust the potential effects of sex and gender on acute heart failure and arrhythmia, but begin to outline areas that EM researchers attending the Academic Emergency Medicine consensus conference “Gender-Specific Research in Emergency Medicine: Investigate, Understand, and Translate How Gender Affects Patient Outcomes” agreed on as having the greatest potential for improving patient outcomes, and directly relate to our specialty of emergency care.

Acknowledgments

Funding: The consensus conference was supported by grant 1R13NS087861-01 from the National Institute of Neurological Disorders and Stroke and the Office of Research on Women’s Health at the NIH. Additional funding was provided by several organizational, institutional, and individual donors. Non-CME events were supported by Janssen Pharmaceuticals and Besins Critical Care/BH Pharma. See the Executive Summary elsewhere in this issue for full funding information.

Footnotes

Breakout session attendees: Blair Alden Parry, John Ashurst, Anise Ayodola, Kevin Barr, Lance Becker, Jeremy Brown, Robert Cannon, Anna Marie Chang, Alan Cherney, Ted Christopher, Laura Costelloe, Steven Deutsch, Holli DeVon, Gail D’Onofrio, Carole Douriez, Nina Gentile, Liz Goldberg, Brooke Harris, Erik Hess, Judd Hollander, Tami Kayea, Jennifer Kruse, Marianne Legato, Richard MacKenzie, Tracy Madsen, Alyson McGregor, Andrew Miller, Chris Moore, Bryan Mumma, Anthony Napoli, Katie O’Conor, Sarah Perman, Basmah Safdar, Jane Scott, Todd Sergel, Shameen Smamji, Howard Smithline, Danic Stone, Dorai Suprina, Deepak Vatti, Kevin Weaver, Michael Weigner, Jane Wigginton, Charles Wira, Jennette Wolfe

References

  • 1.Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009;119:2516–25. doi: 10.1161/CIRCULATIONAHA.108.821306. [DOI] [PubMed] [Google Scholar]
  • 2.Mehta PA, Cowie MR. Gender and heart failure: a population perspective. Heart. 2006;92(Suppl 3):iii14–8. doi: 10.1136/hrt.2005.070342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Hugli O, Braun JE, Kim S, Pelletier AJ, Camargo CA., Jr United States emergency department visits for acute decompensated heart failure, 1992 to 2001. Am J Cardiol. 2005;96:1537–42. doi: 10.1016/j.amjcard.2005.07.064. [DOI] [PubMed] [Google Scholar]
  • 4.Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997;133:703–12. doi: 10.1016/s0002-8703(97)70173-x. [DOI] [PubMed] [Google Scholar]
  • 5.Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44. doi: 10.1161/CIR.0b013e31820a55f5. [DOI] [PubMed] [Google Scholar]
  • 6.Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162:1682–8. doi: 10.1001/archinte.162.15.1682. [DOI] [PubMed] [Google Scholar]
  • 7.Hsich EM, Pina IL. Heart failure in women: a need for prospective data. J Am Coll Cardiol. 2009;54:491–8. doi: 10.1016/j.jacc.2009.02.066. [DOI] [PubMed] [Google Scholar]
  • 8.Safdar B, Greenberg MR. Conference on gender-specific research in emergency care – an executive summary. Acad Emerg Med. 2014 doi: 10.1111/acem.12530. this issue. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Safdar B, Nagurney JT, Anise A, et al. Gender-specific research for emergency diagnosis and management of ischemic heart disease: proceedings from the 2014 AEM consensus conference cardiovascular research workgroup. Acad Emerg Med. 2014 doi: 10.1111/acem.12527. this issue. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Gaasch WH. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA. 1994;271:1276–80. [PubMed] [Google Scholar]
  • 11.Scantlebury DC, Borlaug BA. Why are women more likely than men to develop heart failure with preserved ejection fraction? Curr Opin Cardiol. 2011;26:562–8. doi: 10.1097/HCO.0b013e32834b7faf. [DOI] [PubMed] [Google Scholar]
  • 12.Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation. 2009;119:3070–7. doi: 10.1161/CIRCULATIONAHA.108.815944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Chung AK, Das SR, Leonard D, et al. Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume: the Dallas Heart Study. Circulation. 2006;113:1597–604. doi: 10.1161/CIRCULATIONAHA.105.574400. [DOI] [PubMed] [Google Scholar]
  • 14.Hayward CS, Kalnins WV, Kelly RP. Gender-related differences in left ventricular chamber function. Cardiovasc Res. 2001;49:340–50. doi: 10.1016/s0008-6363(00)00280-7. [DOI] [PubMed] [Google Scholar]
  • 15.Shim CY, Park S, Choi D, et al. Sex differences in central hemodynamics and their relationship to left ventricular diastolic function. J Am Coll Cardiol. 2011;57:1226–33. doi: 10.1016/j.jacc.2010.09.067. [DOI] [PubMed] [Google Scholar]
  • 16.Piro M, Della Bona R, Abbate A, Biasucci LM, Crea F. Sex-related differences in myocardial remodeling. J Am Coll Cardiol. 2010;55:1057–65. doi: 10.1016/j.jacc.2009.09.065. [DOI] [PubMed] [Google Scholar]
  • 17.Nieminen MS, Harjola VP, Hochadel M, et al. Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. Eur J Heart Fail. 2008;10:140–8. doi: 10.1016/j.ejheart.2007.12.012. [DOI] [PubMed] [Google Scholar]
  • 18.Hsich EM, Grau-Sepulveda MV, Hernandez AF, et al. Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. Am Heart J. 2012;163:430–7. doi: 10.1016/j.ahj.2011.12.013. [DOI] [PubMed] [Google Scholar]
  • 19.Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296:2217–26. doi: 10.1001/jama.296.18.2217. [DOI] [PubMed] [Google Scholar]
  • 20.Joseph SM, Novak E, Arnold SV, et al. Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction. Circ Heart Fail. 2013;6:1139–46. doi: 10.1161/CIRCHEARTFAILURE.113.000359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Heo S, Lennie TA, Pressler SJ, Dunbar SB, Chung ML, Moser DK. Factors associated with perceived control and the relationship to quality of life in patients with heart failure. Eur J Cardiovasc Nurs. 2014 doi: 10.1177/1474515113519931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Luttik ML, Jaarsma T, Lesman I, Sanderman R, Hagedoorn M. Quality of life in partners of people with congestive heart failure: gender and involvement in care. J Adv Nurs. 2009;65:1442–51. doi: 10.1111/j.1365-2648.2009.05004.x. [DOI] [PubMed] [Google Scholar]
  • 23.Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309:355–63. doi: 10.1001/jama.2012.216476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail. 2003;5:599–606. doi: 10.1016/s1388-9842(03)00108-9. [DOI] [PubMed] [Google Scholar]
  • 25.Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC., Jr Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976–82. doi: 10.1016/s0735-1097(02)02059-4. [DOI] [PubMed] [Google Scholar]
  • 26.Emdin M, Passino C, Del Ry S, Prontera C, Galetta F, Clerico A. Influence of gender on circulating cardiac natriuretic hormones in patients with heart failure. Clin Chem Lab Med. 2003;41:686–92. doi: 10.1515/CCLM.2003.104. [DOI] [PubMed] [Google Scholar]
  • 27.Nakamura M, Tanaka F, Onoda T, et al. Gender-specific risk stratification with plasma B-type natriuretic peptide for future onset of congestive heart failure and mortality in the Japanese general population. Int J Cardiol. 2010;143:124–9. doi: 10.1016/j.ijcard.2009.01.076. [DOI] [PubMed] [Google Scholar]
  • 28.Knudsen CW, Riis JS, Finsen AV, et al. Diagnostic value of a rapid test for B-type natriuretic peptide in patients presenting with acute dyspnoe: effect of age and gender. Eur J Heart Fail. 2004;6:55–62. doi: 10.1016/j.ejheart.2003.10.006. [DOI] [PubMed] [Google Scholar]
  • 29.Maisel AS, Clopton P, Krishnaswamy P, et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J. 2004;147:1078–84. doi: 10.1016/j.ahj.2004.01.013. [DOI] [PubMed] [Google Scholar]
  • 30.Christ M, Laule-Kilian K, Hochholzer W, et al. Gender-specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea: insights from the B-type natriuretic peptide for acute shortness of breath evaluation study. J Am Coll Cardiol. 2006;48:1808–12. doi: 10.1016/j.jacc.2006.07.037. [DOI] [PubMed] [Google Scholar]
  • 31.Chyu J, Fonarow GC, Tseng CH, Horwich TB. Four-variable risk model in men and women with heart failure. Circ Heart Fail. 2014;7(1):88–95. doi: 10.1161/CIRCHEARTFAILURE.113.000404. [DOI] [PubMed] [Google Scholar]
  • 32.Hsich EM, Grau-Sepulveda MV, Hernandez AF, et al. Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry. Am Heart J. 2013;166:1063–71. doi: 10.1016/j.ahj.2013.08.029. [DOI] [PubMed] [Google Scholar]
  • 33.Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9. doi: 10.1056/NEJMoa052256. [DOI] [PubMed] [Google Scholar]
  • 34.Jong P, McKelvie R, Yusuf S. Should treatment for heart failure with preserved ejection fraction differ from that for heart failure with reduced ejection fraction? BMJ. 2010;341:c4202. doi: 10.1136/bmj.c4202. [DOI] [PubMed] [Google Scholar]
  • 35.Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–81. doi: 10.1016/S0140-6736(03)14285-7. [DOI] [PubMed] [Google Scholar]
  • 36.LeWinter MM, Meyer M. Mechanisms of diastolic dysfunction in heart failure with a preserved ejection fraction: if it’s not one thing it’s another. Circ Heart Fail. 2013;6:1112–5. doi: 10.1161/CIRCHEARTFAILURE.113.000825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Solomon SD, Janardhanan R, Verma A, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369:2079–87. doi: 10.1016/S0140-6736(07)60980-5. [DOI] [PubMed] [Google Scholar]
  • 38.Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309:781–91. doi: 10.1001/jama.2013.905. [DOI] [PubMed] [Google Scholar]
  • 39.Yamamoto K, Origasa H, Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF) Eur J Heart Fail. 2013;15:110–8. doi: 10.1093/eurjhf/hfs141. [DOI] [PubMed] [Google Scholar]
  • 40.Greiten LE, Holditch SJ, Arunachalam SP, Miller VM. Should there be sex-specific criteria for the diagnosis and treatment of heart failure? J Cardiovasc Transl Res. 2014;7(2):138–55. doi: 10.1007/s12265-013-9514-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Whitson HE, Landerman LR, Newman AB, Fried LP, Pieper CF, Cohen HJ. Chronic medical conditions and the sex-based disparity in disability: the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci. 2010;65:1325–31. doi: 10.1093/gerona/glq139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report From the American Heart Association. Circulation. 2014;129(3):e28–292. doi: 10.1161/01.cir.0000441139.02102.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.O’Meara E, Clayton T, McEntegart MB, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007;115:3111–20. doi: 10.1161/CIRCULATIONAHA.106.673442. [DOI] [PubMed] [Google Scholar]
  • 44.Meyer S, van der Meer P, Massie BM, et al. Sex-specific acute heart failure phenotypes and outcomes from PROTECT. Eur J Heart Fail. 2013;15:1374–81. doi: 10.1093/eurjhf/hft115. [DOI] [PubMed] [Google Scholar]
  • 45.Shah AN, Mentz RJ, Gheorghiade M, et al. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial) Am J Cardiol. 2012;110:1803–8. doi: 10.1016/j.amjcard.2012.08.016. [DOI] [PubMed] [Google Scholar]
  • 46.Klempfner R, Koifman E, Goldenberg I, Hamdan A, Tofler GH, Kopel E. The Israel nationwide heart failure survey: sex differences in early and late mortality for hospitalized heart failure patients. J Card Fail. 2014;20(3):193–8. doi: 10.1016/j.cardfail.2013.12.016. [DOI] [PubMed] [Google Scholar]
  • 47.Galvao M, Kalman J, DeMarco T, et al. Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) J Card Fail. 2006;12:100–7. doi: 10.1016/j.cardfail.2005.09.005. [DOI] [PubMed] [Google Scholar]
  • 48.Rodriguez LM, de Chillou C, Schlapfer J, et al. Age at onset and gender of patients with different types of supraventricular tachycardias. Am J Cardiol. 1992;70:1213–5. doi: 10.1016/0002-9149(92)90060-c. [DOI] [PubMed] [Google Scholar]
  • 49.Rosano GM, Leonardo F, Sarrel PM, Beale CM, De Luca F, Collins P. Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet. 1996;347:786–8. doi: 10.1016/s0140-6736(96)90867-3. [DOI] [PubMed] [Google Scholar]
  • 50.Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 2003;91:39D–44D. doi: 10.1016/s0002-9149(02)03378-7. [DOI] [PubMed] [Google Scholar]
  • 51.Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation. 1998;97:2237–44. doi: 10.1161/01.cir.97.22.2237. [DOI] [PubMed] [Google Scholar]
  • 52.Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke. 1999;30:1223–9. doi: 10.1161/01.str.30.6.1223. [DOI] [PubMed] [Google Scholar]
  • 53.Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290:1049–56. doi: 10.1001/jama.290.8.1049. [DOI] [PubMed] [Google Scholar]
  • 54.Dickstein K, Vardas PE, Auricchio A, et al. 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Europace. 2010;12:1526–36. doi: 10.1093/europace/euq392. [DOI] [PubMed] [Google Scholar]
  • 55.Humphries KH, Kerr CR, Connolly SJ, et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation. 2001;103:2365–70. doi: 10.1161/01.cir.103.19.2365. [DOI] [PubMed] [Google Scholar]
  • 56.Paquette M, Roy D, Talajic M, et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol. 2000;86:764–8. doi: 10.1016/s0002-9149(00)01077-8. [DOI] [PubMed] [Google Scholar]
  • 57.Dagres N, Nieuwlaat R, Vardas PE, et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol. 2007;49:572–7. doi: 10.1016/j.jacc.2006.10.047. [DOI] [PubMed] [Google Scholar]
  • 58.Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Behlouli H, Pilote L. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA. 2012;307:1952–8. doi: 10.1001/jama.2012.3490. [DOI] [PubMed] [Google Scholar]
  • 59.Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50:309–15. doi: 10.1016/j.jacc.2007.01.098. [DOI] [PubMed] [Google Scholar]
  • 60.Poli D, Antonucci E, Testa S, Ageno W, Palareti G. Gender differences of bleeding and stroke risk in very old atrial fibrillation patients on VKA treatment: results of the EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics) Thromb Res. 2013;131:12–6. doi: 10.1016/j.thromres.2012.10.009. [DOI] [PubMed] [Google Scholar]
  • 61.Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. doi: 10.1056/NEJMoa0905561. [DOI] [PubMed] [Google Scholar]
  • 62.Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157:805–10. doi: 10.1016/j.ahj.2009.02.005. [DOI] [PubMed] [Google Scholar]
  • 63.Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. doi: 10.1056/NEJMoa1107039. [DOI] [PubMed] [Google Scholar]
  • 64.Forleo GB, Tondo C, De Luca L, et al. Gender-related differences in catheter ablation of atrial fibrillation. Europace. 2007;9:613–20. doi: 10.1093/europace/eum144. [DOI] [PubMed] [Google Scholar]
  • 65.Kannel WB, Wilson PW, D’Agostino RB, Cobb J. Sudden coronary death in women. Am Heart J. 1998;136:205–12. doi: 10.1053/hj.1998.v136.90226. [DOI] [PubMed] [Google Scholar]
  • 66.Teodorescu C, Reinier K, Uy-Evanado A, et al. Survival advantage from ventricular fibrillation and pulseless electrical activity in women compared to men: the Oregon Sudden Unexpected Death Study. J Interv Card Electrophysiol. 2012;34:219–25. doi: 10.1007/s10840-012-9669-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Zareba W, Moss AJ, Jackson Hall W, et al. Clinical course and implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction. J Cardiovasc Electrophysiol. 2005;16:1265–70. doi: 10.1111/j.1540-8167.2005.00224.x. [DOI] [PubMed] [Google Scholar]
  • 68.Hernandez AF, Fonarow GC, Liang L, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA. 2007;298:1525–32. doi: 10.1001/jama.298.13.1525. [DOI] [PubMed] [Google Scholar]
  • 69.Yamac H, Bultmann I, Sliwa K, Hilfiker-Kleiner D. Prolactin: a new therapeutic target in peripartum cardiomyopathy. Heart. 2010;96:1352–7. doi: 10.1136/hrt.2009.179218. [DOI] [PubMed] [Google Scholar]
  • 70.Mielniczuk LM, Williams K, Davis DR, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol. 2006;97:1765–8. doi: 10.1016/j.amjcard.2006.01.039. [DOI] [PubMed] [Google Scholar]
  • 71.Sliwa K, Forster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006;27:441–6. doi: 10.1093/eurheartj/ehi481. [DOI] [PubMed] [Google Scholar]
  • 72.Hilfiker-Kleiner D, Sliwa K, Drexler H. Peripartum cardiomyopathy: recent insights in its pathophysiology. Trends Cardiovasc Med. 2008;18:173–9. doi: 10.1016/j.tcm.2008.05.002. [DOI] [PubMed] [Google Scholar]
  • 73.Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128:589–600. doi: 10.1016/j.cell.2006.12.036. [DOI] [PubMed] [Google Scholar]
  • 74.Forster O, Hilfiker-Kleiner D, Ansari AA, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2008;10:861–8. doi: 10.1016/j.ejheart.2008.07.005. [DOI] [PubMed] [Google Scholar]
  • 75.Rafik Hamad R, Larsson A, Pernow J, Bremme K, Eriksson MJ. Assessment of left ventricular structure and function in preeclampsia by echocardiography and cardiovascular biomarkers. J Hypertens. 2009;27:2257–64. doi: 10.1097/HJH.0b013e3283300541. [DOI] [PubMed] [Google Scholar]
  • 76.Resnik JL, Hong C, Resnik R, et al. Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol. 2005;193:450–4. doi: 10.1016/j.ajog.2004.12.006. [DOI] [PubMed] [Google Scholar]
  • 77.Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet. 2006;368:687–93. doi: 10.1016/S0140-6736(06)69253-2. [DOI] [PubMed] [Google Scholar]
  • 78.Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121:1465–73. doi: 10.1161/CIRCULATIONAHA.109.901496. [DOI] [PubMed] [Google Scholar]
  • 79.Sliwa K, Woodiwiss A, Candy G, et al. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol. 2002;90:1118–22. doi: 10.1016/s0002-9149(02)02779-0. [DOI] [PubMed] [Google Scholar]
  • 80.Staudt A, Schaper F, Stangl V, et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation. 2001;103:2681–6. doi: 10.1161/01.cir.103.22.2681. [DOI] [PubMed] [Google Scholar]
  • 81.Cooper LT., Jr The natural history and role of immunoadsorption in dilated cardiomyopathy. J Clin Apher. 2005;20:256–60. doi: 10.1002/jca.20045. [DOI] [PubMed] [Google Scholar]

RESOURCES